Definium Therapeutics says Phase 3 Emerge trial of DT120 ODT in major depressive disorder meets primary endpoint

Definium Therapeutics, Inc.

Definium Therapeutics, Inc.

DFTX

0.00
  • Definium Therapeutics reported positive topline results from its Phase 3 Emerge trial of DT120 ODT in major depressive disorder.
  • The study met its primary endpoint, showing a clinically meaningful improvement versus placebo with a rapid onset and durable benefit.
  • Key secondary endpoints also favored DT120, supporting a broad efficacy profile across symptom severity and global clinical status.
  • Safety was generally favorable, with mostly mild-to-moderate side effects and no serious adverse events or suicidality signal reported.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606220700BIZWIRE_USPR_____20260622_BW572802) on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.